Hyperprogression after nivolumab for the treatment of melanoma

Indian J Dermatol Venereol Leprol. 2023 Jul-Aug;89(4):616-617. doi: 10.25259/IJDVL_160_2021.
No abstract available

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Humans
  • Melanoma* / drug therapy
  • Nivolumab* / adverse effects

Substances

  • Nivolumab